The inhibition of PARP but not EGFR results in the radiosensitization of HPV/p16-positive HNSCC cell lines

Radiotherapy and Oncology

Volumn 113, Issue 3, 2014, Pages 345-351

  Güster, Julian David ^a   Weissleder, Stephanie Valerie ^a   Busch, Chia Jung ^a   Kriegs, Malte ^a   Petersen, Cordula ^a   Knecht, Rainald ^a   Dikomey, Ekkehard ^a   Rieckmann, Thorsten ^a  

^a Center Hamburg Eppendorf   (Germany)

Author keywords

Chk1; EGFR; HNSCC; HPV; PARP; Radiosensitivity

Indexed keywords

CETUXIMAB; CHECKPOINT KINASE 1; ENZYME INHIBITOR; EPIDERMAL GROWTH FACTOR RECEPTOR; MONOCLONAL ANTIBODY; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE INHIBITOR; OLAPARIB; PF 00477736; PROTEIN P16; RADIOSENSITIZING AGENT; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; CYCLIN DEPENDENT KINASE INHIBITOR 2A;

ARTICLE; CANCER CELL LINE; CANCER RADIOTHERAPY; CELL CYCLE; CELL PROLIFERATION ASSAY; CONTROLLED STUDY; DRUG EFFECT; ENZYME INHIBITION; G2 PHASE CELL CYCLE CHECKPOINT; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; HUMAN CELL; NONHUMAN; PHASE 3 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RADIATION DOSE; RADIOSENSITIZATION; WART VIRUS; WESTERN BLOTTING; X IRRADIATION; ANTAGONISTS AND INHIBITORS; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; FLUORESCENT ANTIBODY TECHNIQUE; GENETICS; HEAD AND NECK NEOPLASMS; PAPILLOMAVIRIDAE; PROCEDURES; RADIATION RESPONSE; TUMOR CELL CULTURE; VIROLOGY;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CARCINOMA, SQUAMOUS CELL; CELL SURVIVAL; CYCLIN-DEPENDENT KINASE INHIBITOR P16; FLUORESCENT ANTIBODY TECHNIQUE; HEAD AND NECK NEOPLASMS; HUMANS; PAPILLOMAVIRIDAE; POLY(ADP-RIBOSE) POLYMERASES; RADIATION-SENSITIZING AGENTS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TUMOR CELLS, CULTURED;

EID: 84915737153     PISSN: 01678140     EISSN: 18790887     Source Type: Journal    
DOI: 10.1016/j.radonc.2014.10.011     Document Type: Article

References (36)

1. K.K. Ang, and E.M. Sturgis Human papillomavirus as a marker of the natural history and response to therapy of head and neck squamous cell carcinoma Semin Radiat Oncol 22 2012 128 142
2. G.C. Blitzer, M.A. Smith, S.L. Harris, and R.J. Kimple Review of the clinical and biologic aspects of human papillomavirus-positive squamous cell carcinomas of the head and neck Int J Radiat Oncol, Biol, Phys 88 2014 761 770
3. J.A. Bonner, P.M. Harari, and J. Giralt Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck New Engl J Med 354 2006 567 578
4. C.J. Busch, M. Kriegs, and S. Laban HPV-positive HNSCC cell lines but not primary human fibroblasts are radiosensitized by the inhibition of Chk1 Radiother Oncol 108 2013 495 499
5. A.J. Chalmers, M. Lakshman, N. Chan, and R.G. Bristow Poly(ADP-ribose) polymerase inhibition as a model for synthetic lethality in developing radiation oncology targets Semin Radiat Oncol 20 2010 274 281
6. A.K. Chaturvedi, W.F. Anderson, and J. Lortet-Tieulent Worldwide trends in incidence rates for oral cavity and oropharyngeal cancers J Clin Oncol 31 2013 4550 4559
7. P. Chinnaiyan, S. Huang, and G. Vallabhaneni Mechanisms of enhanced radiation response following epidermal growth factor receptor signaling inhibition by erlotinib (Tarceva) Cancer Res 65 2005 3328 3335
8. R. Dok, P. Kalev, and E.J. Van Limbergen P16/INK4A impairs homologous recombination-mediated DNA repair in human papillomavirus (HPV) positive-head and neck tumors Cancer Res 2014
9. J.G. Eriksen, C. Maare, and J. Johansen Evaluation of the EGFR-inhibitor zalutumumab given with primary curative (chemo)radiation therapy to patients with squamous cell carcinoma of the head and neck: results of the DAHANCA 19 randomized phase 3 trial Int J Radiat Oncol, Biol, Phys 88 2014 465 (suppl.)
10. C. Fakhry, W.H. Westra, and S. Li Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial J Nat Cancer Inst 100 2008 261 269
11. C. Godon, F.P. Cordelieres, and D. Biard PARP inhibition versus PARP-1 silencing: different outcomes in terms of single-strand break repair and radiation susceptibility Nucleic Acids Res 36 2008 4454 4464
12. R.J. Kimple, M.A. Smith, and G.C. Blitzer Enhanced radiation sensitivity in HPV-positive head and neck cancer Cancer Res 73 2013 4791 4800
13. P. Lassen The role of human papillomavirus in head and neck cancer and the impact on radiotherapy outcome Radiother Oncol 95 2010 371 380
14. P. Lassen, J.G. Eriksen, S. Hamilton-Dutoit, T. Tramm, J. Alsner, and J. Overgaard Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck J Clin Oncol 27 2009 1992 1998
15. D.A. Loser, A. Shibata, A.K. Shibata, L.J. Woodbine, P.A. Jeggo, and A.J. Chalmers Sensitization to radiation and alkylating agents by inhibitors of poly(ADP-ribose) polymerase is enhanced in cells deficient in DNA double-strand break repair Mol Cancer Ther 9 2010 1775 1787
16. R.E. Meyn, A. Munshi, J.V. Haymach, L. Milas, and K.K. Ang Receptor signaling as a regulatory mechanism of DNA repair Radiother Oncol 92 2009 316 322
17. H. Mirghani, F. Amen, and P. Blanchard Treatment de-escalation in HPV-positive oropharyngeal carcinoma: Ongoing trials, critical issues and perspectives Int J Cancer 2014 10.1002/ijc.28847
18. H. Mirghani, F. Amen, F. Moreau, J. Guigay, D.M. Hartl, and J. Lacau St Guily Oropharyngeal cancers: relationship between epidermal growth factor receptor alterations and human papillomavirus status Eur J Cancer 50 2014 1100 1111
19. C.A. Moody, and L.A. Laimins Human papillomavirus oncoproteins: pathways to transformation Nat Rev 10 2010 550 560
20. M.A. Morgan, L.A. Parsels, and L. Zhao Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair Cancer Res 70 2010 4972 4981
21. B. Mukherjee, H. Choy, C. Nirodi, and S. Burma Targeting nonhomologous end-joining through epidermal growth factor receptor inhibition: rationale and strategies for radiosensitization Semin Radiat Oncol 20 2010 250 257
22. B. O'Sullivan, S.H. Huang, and B. Perez-Ordonez Outcomes of HPV-related oropharyngeal cancer patients treated by radiotherapy alone using altered fractionation Radiother Oncol 103 2012 49 56
23. B. Pajares, J.M. Trigo, and M.D. Toledo Differential outcome of concurrent radiotherapy plus epidermal growth factor receptor inhibitors versus radiotherapy plus cisplatin in patients with human papillomavirus-related head and neck cancer BMC Cancer 13 2013 26
24. R. Plummer Poly(ADP-ribose)polymerase (PARP) inhibitors: from bench to bedside Clin Oncol 26 2014 250 256 (Royal College of Radiologists (Great Britain))
25. C. Powell, C. Mikropoulos, and S.B. Kaye Pre-clinical and clinical evaluation of PARP inhibitors as tumour-specific radiosensitisers Cancer Treat Rev 36 2010 566 575
26. N. Riaz, E. Sherman, and L. Koutcher Concurrent chemoradiotherapy with cisplatin versus cetuximab for squamous cell carcinoma of the head and neck Am J Clin Oncol 2014 10.1097/COC.0000000000000006
27. T. Rieckmann, S. Tribius, and T.J. Grob HNSCC cell lines positive for HPV and p16 possess higher cellular radiosensitivity due to an impaired DSB repair capacity Radiother Oncol 107 2013 242 246
28. M.M. Rietbergen, C.R. Leemans, and E. Bloemena Increasing prevalence rates of HPV attributable oropharyngeal squamous cell carcinomas in the Netherlands as assessed by a validated test algorithm Int J Cancer 132 2013 1565 1571
29. D.I. Rosenthal, P.M. Harari, and J. Giralt Impact of p16 status on the results of the phase III cetuximab (cet)/radiotherapy (RT) J Clin Oncol 32 2014 5s (suppl.; abstr. 6001)
30. M. Rouleau, A. Patel, M.J. Hendzel, S.H. Kaufmann, and G.G. Poirier PARP inhibition: PARP1 and beyond Nat Rev 10 2010 293 301
31. B.S. Sorensen, M. Busk, and N. Olthof Radiosensitivity and effect of hypoxia in HPV positive head and neck cancer cells Radiother Oncol 108 2013 500 505
32. C.S. Sorensen, L.T. Hansen, and J. Dziegielewski The cell-cycle checkpoint kinase Chk1 is required for mammalian homologous recombination repair Nat Cell biol 7 2005 195 201
33. R.M. Srivastava, S.C. Lee, and P.A. Andrade Filho Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients Clin Cancer Res 19 2013 1858 1872
34. Y. Tang, H.A. Hamed, A. Poklepovic, Y. Dai, S. Grant, and P. Dent Poly(ADP-ribose) polymerase 1 modulates the lethality of CHK1 inhibitors in mammary tumors Mol Pharmacol 82 2012 322 332
35. S. Vance, E. Liu, and L. Zhao Selective radiosensitization of p53 mutant pancreatic cancer cells by combined inhibition of Chk1 and PARP1 Cell Cycle 10 2011 4321 4329 (Georgetown, Tex)
36. M. Wang, F. Morsbach, and D. Sander EGF receptor inhibition radiosensitizes NSCLC cells by inducing senescence in cells sustaining DNA double-strand breaks Cancer Res 71 2011 6261 6269